The DOI matches its Crossref record.
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial
Open accessAbstract
Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes are dismal, but early phase I/II studies have suggested promising activity and acceptable toxicity using the novel polydisperse oligonucleotide defibrotide. This randomized phase II dose-finding trial determined the efficacy of defibrotide in patients with severe VOD following hematopoietic stem cell transplantation (HSCT) and identified an appropriate dose for future trials. Adult and pediatric patients received either lower-dose (arm A: 25 mg/kg/day; n = 75) or higher-dose (arm B: 40 mg/kg/day; n = 74) i.v. defibrotide administered in divided doses every 6 hours for > or =14 days or until complete response, VOD progression, or any unacceptable toxicity occurred. Overall complete response and day +100 post-HSCT survival rates were 46% and 42%, respectively, with no significant difference between treatment arms. The incidence of treatment-related adverse events was low (8% overall; 7% in arm A, 10% in arm B); there was no significant difference in the overall rate of adverse events between treatment arms. Early stabilization or decreased bilirubin was associated with better response and day +100 survival, and decreased plasminogen activator inhibitor type 1 (PAI-1) during treatment was associated with better outcome; changes were similar in both treatment arms. Defibrotide 25 or 40 mg/kg/day also appears effective in treating severe VOD following HSCT. In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day was selected for ongoing phase III trials in VOD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.130 · Cited by 543
Self-citationCorbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A., Boelens, J. J., Hewitt, A., Schrum, J., Schulz, A. S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61938-7 · Cited by 375
Self-citationCorbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationJodele, S., Laskin, B. L., Dandoy, C. E., Myers, K. C., El-Bietar, J., Davies, S. M., Goebel, J., & Dixon, B. P. (2015) · Blood Reviews · doi:10.1016/j.blre.2014.11.001 · Cited by 353
Dignan, F. L., Wynn, R. F., Hadzic, N., Karani, J., Quaglia, A., Pagliuca, A., Veys, P., & Potter, M. N. (2013) · British Journal of Haematology · doi:10.1111/bjh.12558 · Cited by 295
Metadata
- Authors
- Richardson, P. G., Soiffer, R. J., Antin, J. H., Uno, H., Jin, Z., Kurtzberg, J., Martin, P. L., Steinbach, G., Murray, K. F., Vogelsang, G. B., Chen, A. R., Krishnan, A., Kernan, N. A., Avigan, D. E., Spitzer, T. R., Shulman, H. M., Di Salvo, D. N., Revta, C., Warren, D., Momtaz, P., Bradwin, G., Wei, L. J., Iacobelli, M., McDonald, G. B., & Guinan, E. C.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 16
- Issue
- 7
- Pages
- 1005-1017
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W1973519172
- Cited by
- 237
- References
- 0
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. https://app.cochat.ai/papers/10.1016/j.bbmt.2010.02.009
- The paper
- Richardson, P. G., Soiffer, R. J., Antin, J. H., Uno, H., Jin, Z., Kurtzberg, J., Martin, P. L., Steinbach, G., Murray, K. F., Vogelsang, G. B., Chen, A. R., Krishnan, A., Kernan, N. A., Avigan, D. E., Spitzer, T. R., Shulman, H. M., Di Salvo, D. N., Revta, C., Warren, D., . . . Guinan, E. C. (2010). Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2010.02.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.